• Oct 26, 2026

  $29.79-0.80%

  Pfizer shares closed down 0.80%. Seeking Alpha reported that the Talzenna/Xtandi combination was approved for an earlier prostate cancer setting [1]. The other two headlines concerned different companies, so they do not explain the move.

  • 1Seeking Alpha

• Oct 23, 2026

  $30.03-1.28%

  Comparable pharmaceutical companies fell 1.04% on average, with 4 of 6 declining [1]. Pfizer's 1.28% drop came alongside that sector-wide weakness rather than against it [1].

  • 1Peer group

• Oct 22, 2026

  $30.42+1.91%

  Pfizer rose 1.91% while comparable pharmaceutical companies moved +1.19% on average, with 5 of 6 rising [1]. Pfizer's gain was larger than the cohort average, and the move came alongside a mostly positive group rather than on a company-specific report [1].

  • 1Peer group

• Oct 21, 2026

  $29.85-0.86%

• Oct 20, 2026

  $30.11+2.28%

  Comparable listed companies in Pharmaceutical Preparations rose 2.43% on average, with 5 of 6 rising [1]. The shares rose 2.28%, in line with that cohort move [1].

  • 1Peer group

• Oct 19, 2026

  $29.44-0.47%

  Pfizer slipped 0.47% while comparable pharmaceutical companies fell 0.92% on average, with 5 of 6 lower [1]. The stock's small decline was therefore milder than the group's move [1].

  • 1Peer group

• Oct 16, 2026

  $29.58+0.48%

  Pfizer closed up 0.48%. Seeking Alpha reported that Pfizer was among the winners of EU drug recommendations this month [1]. The Motley Fool wrote that Pfizer had declared its 352nd straight quarterly dividend [2]. Neither item ties the day's move to these developments.

  • 1Seeking Alpha
  • 2The Motley Fool

Closing prices for PFE. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.